Medication Description: Ceruloplasmin (Ceruloplasminum)
Glycoprotein a-globulin fraction of human serum.
Available for medical use in the form of a lyophilized amorphous powder or a porous mass of blue (Blue color due to the content of copper ions in the glycoprotein.). Soluble in water, forms a weakly palerescent blue solution. Hygroscopic.
Ceruloplasmin is a plasma protein that performs a number of important biological functions in the body; increases the stability of cell membranes, is involved in immunological reactions, ion exchange, has an antioxidant effect, inhibits lipid peroxidation, stimulates hematopoiesis. The serum content of ceruloplasmin is significantly reduced in hepatocerebral degeneration (Wilson's disease - Konovalov), which is an important diagnostic indicator.
As a drug used to stimulate hematopoiesis, reduce toxicity and immunological correction in the treatment of cancer patients; in the period of preoperative preparation in debilitated patients with anemia, exhaustion, intoxication; in the early postoperative period in the case of massive blood loss during surgery; in case of purulent-septic complications in the early postoperative chemotherapy of cancer patients, including in patients with hemoblastosis and mild intoxication.
Ceruloplasmin is also used in the treatment of patients with acute and chronic osteomyelitis.
Injected intravenously (30 drops per minute). The contents of 1 vial or ampoule is dissolved in 200 ml of 5% glucose solution or isotonic sodium chloride solution.
Oncological patients during the preoperative preparation period, ceruloplasmin is administered in a dose of 1, 5, 2, 0 mg / kg; a course of treatment of 7 to 10 injections (daily or every other day, depending on the patient’s condition)
In the postoperative period, a single dose is determined by the amount of blood loss and ranges from 1.5 mg / kg (with low blood loss) to 6 mg / kg (with large blood loss); The course of treatment consists of daily (1 time per day) infusion for 7–10 days.
During chemoradiation treatment, a single dose is 4–6 mg / kg, the course of treatment consists of 10–14 injections (3 injections per week). For patients with hemoblastosis, a single dose is 1, 5, 3, 0 mg / kg, a course of treatment with 7 to 10 injections, administered daily 1 time per day.
In acute osteomyelitis, a single dose of 2.5 mg / kg, the course of treatment consists of 5 injections administered daily or every other day. In chronic osteomyelitis, ceruloplasmin is administered 5 mg / kg 2 to 3 times with an interval of 1 to 2 days and then 3 to 7 injections of 2, 5 mg / kg every other day are given.
At the beginning of treatment with ceruloplasmin, a sensation of flushing to the face, nausea, chills, a short-term increase in body temperature may appear; skin rash (urticaria). In these cases, reduce the dose, reduce the speed of administration or cancel the drug.